Patton Fund Management Inc. has taken a position in bio-research company
Charles River Laboratories International. The company has faced challenges being underperforming the Nasdaq andwith stock market fluctuations dragging its share down. The company has just announced new oncology partnerships with
PICI and
CHLA as it reaffirms its
2025 earnings guidance. The firm also unveiled its plans to present its performance at
Baird and Morgan Stanley conferences. Amidst all these, the company recently announced a
CFO transition, a decision that may present the potential to alter its investment story. Here, it is noted that their
2nd Quarter 2025 earnings beat revenue expectations while EPS lagged. Despite the volatility, several firms, including
Riverbridge Partners LLC and
Goldman Sachs, continue to maintain high stakes in Charles River. The
full-year 2024 earnings reveal a miss in EPS expectations while recent
Q2 earnings were notable for their surge past estimates along with a raised outlook.
Charles River Laboratories International CRL News Analytics from Fri, 14 Feb 2025 08:00:00 GMT to Sat, 27 Sep 2025 11:38:27 GMT -
Rating 3
- Innovation 5
- Information 5
- Rumor -5
